Human uPA Total Antigen Assay

Strip well format. Reagents for up to 96 tests.

For Research Use Only.

INTENDED USE

Human uPA total antigen assay is intended for the quantitative determination of total plasminogen activator antigen in biological fluids.

BACKGROUND

Urokinase plasminogen activator is a serine protease that activates plasminogen to plasmin in the blood fibrinolytic system. It is also implicated in events related to cell invasion/migration [1].

ASSAY PRINCIPLE

Human uPA will bind to the capture antibody coated on the microtiter plate. Free and complexed enzyme will react with the capture antibody on the plate. After appropriate washing polyclonal anti-human uPA primary antibody binds to the captured enzyme. Excess antibody is washed away and bound polyclonal antibody is then reacted with the secondary antibody conjugated to horseradish peroxidase. TMB substrate is used for color development at 450nm. A standard calibration curve is prepared along with the samples to be measured using dilutions of uPA.

REAGENTS PROVIDED

♦ Coated plate:

1-96 well immulon plate coated, blocked, and dried with capture antibody

♦ 10X Wash Buffer:

1 bottle of 50ml wash buffer; bring to 1X using DI water

♦ Human uPA activity standard:

1 vial lyophilized standard

♦ Anti-human uPA primary antibody:

1 vial lyophilized polyclonal anti-human antibody

♦ Anti-rabbit horseradish peroxidase conjugate secondary antibody:

1 vial concentrated HRP labeled antibody

♦TMB substrate solution: 10 ml

STORAGE AND STABILITY

All kit components must be stored at 4°C. Store unopened plate and any unused microtiter strips in the pouch with desiccant. Reconstituted standards and primary may be stored at -70°C for later use. **DO NOT** freeze/thaw the standards and primary antibody more than once. All other unused kit components must be stored at 4°C. Kit should be used no later than the expiration date.

REAGENTS AND EQUIPMENT REQUIRED

- •1-channel pipettes covering 20-200 μl, 500-5000 μl and 200-1000μl
- •12-channel pipette for 30-300μl
- Paper towels or kimwipes
- •1.5ml micro centrifuge tubes
- •1N H₂SO₄
- DI water
- Magnetic stirrer and stir-bars
- Plastic containers with lids

- •TBS buffer
- Blocking buffer
- •Microtiter plate spectrophotometer operable at 450nm
- Microtiter plate shaker with uniform horizontally circular movement up to 300rpm

WARNINGS

Warning – Avoid skin and eye contact when using TMB One substrate solution since it may be irritating to eyes, skin, and respiratory system. Wear safety goggles and gloves.

PRECAUTIONS

- DO NOT mix any reagents or components of this kit with any reagents or components of any other kit. This kit is designed to work properly as provided.
- DO NOT pipette reagents by mouth.
- Always pour substrate out of the bottle into a clean test tube. DO NOT pipette out of the bottle as you could contaminate the substrate.
- Keep plate covered except when adding reagents, washing, or reading.
- DO NOT smoke, drink, or eat in areas where specimens or reagents are being handled.

PREPARATION OF REAGENTS

• TBS buffer:

0.10M TRIS, 0.15M NaCl, pH 7.4

• Blocking buffer: 3% BSA in TBS buffer

SPECIMEN PREPARATION

Samples of human plasma, serum, urine, cell culture media, or tissue extracts may be applied directly to the plate.

The assay measures total uPA in the 0.1-50 ng/ml range. Samples giving uPA levels above 50ng/ml should be diluted in plasma or similar fluid devoid of uPA.

ASSAY PROCEDURE

Perform assay at room temperature. Vigorously shake plate (300rpm) at each step of the assay.

Preparation of Standard:

Prepare the uPA standard according to the dilution table.

Reconstitute vial with 1 ml of BSA, making Human uPA: 500ng/ml

uPA	Dilutions
concentration	
(ng/ml)	
50	900µl (BSA) + 100µl
	(vial)
20	600µl (BSA) + 400µl
	(50ng/ml)
10	500µl (BSA) + 500µl
	(20ng/ml)
5	500µl (BSA) + 500µl
	(10ng/ml)
2	600µl (BSA) + 400µl
	(5ng/ml)
1	500µl (BSA) + 500µl
	(2ng/ml)
0.5	500µl (BSA) + 500µl
	(1ng/ml)
0.25	500µl (BSA) + 500µl
	(0.5ng/ml)
0.1	600µl (BSA) + 400µl
	(0.25ng/ml)

NOTE: DILUTIONS FOR THE STANDARD CURVE MUST BE MADE AND APPLIED TO THE PLATE IMMEDIATELY.

Standard and Unknown Addition:

Remove microtiter plate from bag. Add 100µl standard in duplicate and unknown to wells. Carefully record position of standards and unknowns. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300µl wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

Primary Antibody Addition:

Add 10ml 3% BSA blocking buffer directly to the primary antibody vial and agitate gently to completely dissolve

contents. Add $100\mu l$ to all wells. Shake plate at 300 rpm for 30 minutes. Wash wells three times with $300\mu l$ wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

Secondary Antibody Addition:

Dilute 1 μ l into 10ml of 3% BSA blocking buffer and add 100 μ l to all wells. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300 μ l wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

Substrate Incubation:

Add $100\mu l$ TMB substrate to all wells and shake plate for 2-15 minutes. Quench the reaction by the addition of $50\mu l$ of 1M H_2SO_4 and read final absorbance values at 450nm.

NOTE: Time for substrate development is dependent on needs of researcher.


Measurement:


Set the absorbance at 450nm in a microtiter plate spectrophotometer. Measure the absorbance in all wells at 450nm, A_{450} .

Assay Calibration:

Plot A_{450} against the amount of uPA in the standards. Fit a straight line through the points using a linear fit procedure. The uPA activity in the unknowns can be determined by from this curve.

A typical standard curve. (EXAMPLE ONLY, DO NOT USE)





The concentration of uPA antigen in human plasma has been reported to be 3.5 ± 1.4 ng/ml (mean \pm SD, n = 54) [2]. Culture media of fibroblasts, endothelial-and kidney cells showed antigen levels of 1.2, 23 and 65 ng/ml, respectively [2]. The uPA antigen level in human bile is reported as 0.705 ng/ml [3].

Detergent extracts of human tumor tissues had the following uPA antigen levels [4]:

Cancer	Mean	Range	n
Lung	6.28	(3.33 - 18.23)	6
Cervical	5.03	(2.33 - 8.72)	6
Colon	3.65	(2.30 - 8.80)	6
Melanoma	1.04	(0.62-1.77)	6
Breast	2.67	(0.00 - 8.96)	9

Abnormalities in uPA levels have been reported in the following condition:

- ♦ Venous Thrombosis: Low levels of uPA is associated with clot formation [5].
- ♦ Inflammatory Disease: Low levels of uPA may aggravate this condition [6].

DISCLAIMER

This information is believed to be correct but does not claim to be all-inclusive and shall be used only as a guide. The supplier of this kit shall not be held liable for any damage resulting from handling or from contact with the above product.

REFERENCES

- 1. Kjøller L: The Urokinase Plasminogen Activator Receptor in the Regulation of the Actim Cytoskeleton and Cell Motility. Biol. Chem., **383**: 5-19, 2002.
- 2. Binnema, DJ *et al.*: Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb. Res., **43(5)**: 569-577, 1986.
- 3. Kondera-Anasz, Z et al.: Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits. Med. Sci. Monit., **6(3)**: 616-617, 2000.
- 4. Ferrier, CM *et al.*: Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. British Journal of Cancer, **79(9/10)**: 1534-1541, 1999.
- 4. Singh I, et al.: Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation, **107(6)**: 869-875, 2003.
- 5. Yang YH, et al.: Tissue-type plasminogen activator deficiency exacerbates arthritis. J. Immunol., **167(2)**: 1047-1052, 2001.